# Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

> **NCT00845338** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 7 (actual)

## Conditions studied

- Multiple Sclerosis
- Overactive Detrusor

## Interventions

- **DRUG:** Darifenacin (BAY79-4998)

## Key facts

- **NCT ID:** NCT00845338
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The enrollment rate at most centers was unlikely to result in the recruitment of the planned sample size of 40 evaluable subjects.
- **Last updated:** 2014-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00845338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00845338, "Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00845338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*